{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-005554","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2026-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.986232+00:00","generated_at":"2026-05-16T04:06:42.101781+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Vivos Therapeutics appoints Gregg C. E. Johnson as independent director","bullets":["Gregg C. E. Johnson appointed independent director effective Feb 4, 2026; will serve on Compensation Committee.","Annual cash fee of $48,000 plus $5,000 per committee membership; eligible for stock options under 2024 Equity Incentive Plan.","Johnson previously served as Secretary (2016-2020) and director (2016-2018) of Vivos; has law degree and experience in emerging companies."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-005554","json":"https://secwatch.observer/filing/0001493152-26-005554.json","markdown":"https://secwatch.observer/filing/0001493152-26-005554.md","text":"https://secwatch.observer/filing/0001493152-26-005554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226005554/0001493152-26-005554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226005554/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:06:42.101781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}